


PHARMACEUTICAL 2019




Seres Therapeutics Inc. Rank 257 of 371





PHARMACEUTICAL 2019





The relative strengths and weaknesses of Seres Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Seres Therapeutics Inc. compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 51% points. The greatest weakness of Seres Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 115% points.

The company's Economic Capital Ratio, given in the ranking table, is -314%, being 17% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	92,665
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	42,041
Liabilities, Non-Current	117,010
Other Assets	1,513
Other Compr. Net Income	146
Other Expenses	0
Other Liabilities	9,466
Other Net Income	1,342
Property and Equipment	26,294
Research and Development	95,955
Revenues	28,267
Selling, General and Administrative Expense	32,596

Output Variable	Value in 1000 USD
Assets	120,472
Liabilities	168,517
Expenses	128,551
Stockholders Equity	-48,045
Net Income	-98,942
Comprehensive Net Income	-98,869
Economic Capital Ratio	-314%